Jacobio Pharmaceuticals Group Co Ltd
01167
Company Profile
Business description
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
Contact
No.105 Jinghai 3rd Road
Building 8, Beijing Economic-Technological Development Area
Beijing
CHNT: +86 1056315466
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
196
Stocks News & Analysis
stocks
ASX share undervalued as margins expected to rebound
This ASX share remains overlooked despite a strong outlook.
stocks
Cheap retail REIT with an attractive yield
Lower consumer spending unlikely to buckle this retail REIT.
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,185.90 | 70.20 | 0.77% |
| CAC 40 | 8,454.88 | 7.61 | 0.09% |
| DAX 40 | 24,835.38 | 75.03 | -0.30% |
| Dow JONES (US) | 51,999.67 | 328.64 | 0.64% |
| FTSE 100 | 10,476.22 | 17.99 | -0.17% |
| HKSE | 24,312.16 | 181.79 | -0.74% |
| NASDAQ | 26,376.34 | 307.60 | -1.15% |
| Nikkei 225 | 69,902.25 | 497.75 | 0.72% |
| NZX 50 Index | 13,392.98 | 33.15 | -0.25% |
| S&P 500 | 7,511.35 | 42.94 | -0.57% |
| S&P/ASX 200 | 8,966.30 | 65.50 | 0.74% |
| SSE Composite Index | 4,108.08 | 16.18 | 0.40% |